Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Retained Earnings (2023 - 2025)

Immunome (IMNM) has disclosed Retained Earnings for 3 consecutive years, with -$728.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 41.19% year-over-year to -$728.2 million, compared with a TTM value of -$728.2 million through Dec 2025, down 41.19%, and an annual FY2025 reading of -$728.2 million, down 41.19% over the prior year.
  • Retained Earnings was -$728.2 million for Q4 2025 at Immunome, down from -$658.3 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $22000.0 in Q4 2023 and bottomed at -$728.2 million in Q4 2025.
  • Average Retained Earnings over 3 years is -$287.9 million, with a median of -$241.2 million recorded in 2023.
  • The sharpest move saw Retained Earnings tumbled 2344509.09% in 2024, then skyrocketed 100.0% in 2025.
  • Year by year, Retained Earnings stood at $22000.0 in 2023, then crashed by 2344509.09% to -$515.8 million in 2024, then plummeted by 41.19% to -$728.2 million in 2025.
  • Business Quant data shows Retained Earnings for IMNM at -$728.2 million in Q4 2025, -$658.3 million in Q3 2025, and -$24000.0 in Q2 2025.